top of page
the use of adcs has previously presented challenges in manufacturing, stability, and bioavailability leading to toxicity, lack of efficacy, and drug resistance. araris addresses these major shortcomings, unlocking the potential to drastically simplify and accelerate adc development and manufacturing, and improve safety and tolerability in patients.
accelerating and simplifying adc manufacturing
araris biotech ag is pioneering the development of a novel, proprietary antibody-drug conjugate (adc)-linker technology. araris’ platform technology links highly potent cytotoxic agents to off-the-shelf antibodies, thus forming adcs.
developing novel adc-linker technology
rac IV
biotech
2019
2019
fund
sector
invested in
founded
araris founders
bottom of page